Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 1/2000

01-12-2000 | Review Article

The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents

Author: Dr Eric K. Rowinsky

Published in: Drugs | Special Issue 1/2000

Login to get access
Metadata
Title
The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents
Author
Dr Eric K. Rowinsky
Publication date
01-12-2000
Publisher
Springer International Publishing
Published in
Drugs / Issue Special Issue 1/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200060001-00001

Other articles of this Special Issue 1/2000

Drugs 1/2000 Go to the issue

Questions and Answers

Questions and Answers

Review Article

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents

Review Article

ZD1839 (‘Iressa’)1,2 as an Anticancer Agent

Review Article

Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy